TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16243988
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg plus Dexamethasone 8 mg (O+D)
Study: 12195324
Drug: Wireless capsule
Normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wireless capsule endoscopy (CE)
Study: 23654110
Drug: 3% L-arabinose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% L-arabinose
Study: 23654110
Drug: 5% L-arabinose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% L-arabinose
Study: 23654110
Drug: 10% L-arabinose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% L-arabinose
Study: 23654110
Drug: L-arabinose (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arabinose (daily for six months)
Study: 21713377
Drug: Intracoronary adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary adenosine administration
Study: 18718892
Drug: FOLFIRI (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI (irinotecan 180 mg/m² on day 1 + 5-fluorouracil 400 mg/m² bolus and 600 mg/m² 22-h infusion + leucovorin 200 mg/m² on days 1-2, every 2 weeks)
Study: 18718892
Drug: FUIRI (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUIRI (irinotecan 80 mg/m² + 5-fluorouracil 2,250 mg/m² 48-h infusion, weekly)
Study: 17008196
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches (21 mg)
Study: 17008196
Drug: Nicotine lozenges
Normalized name: nicotine Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine lozenges (4 mg)
Study: 9714485
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment of aortic coarctation
Study: 7978588
Drug: Nasal midazolam
Normalized name: midazolam Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal midazolam (0.25 mg/kg)
Study: 2657523
Drug: Topical benzocaine
Normalized name: benzocaine Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzocaine 20% gel
Study: 25751123
Drug: Nonspecific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonspecific treatment factors in child and parent sessions
Study: 25751123
Drug: Nonspecific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonspecific treatment factors in parent intervention
Study: 17117692
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (0.4 mgr/0.2 ml) applied in 150 patients for 5 minutes during surgery
Study: 15001969
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL normal-strength orange juice
Study: 11286609
Drug: Baclofen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (40 mg maximum daily dose, given three times per day)
Study: 11286609
Drug: Clonidine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.8 mg maximum daily dose, given three times per day)
Study: 8430057
Drug: metoprolol CR/ZOK
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol CR/ZOK (95 mg metoprolol succinate)
Study: 8430057
Drug: metoprolol OROS
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol OROS (95 mg metoprolol fumarate)
Study: 8430057
Drug: immediate-release tablet
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: immediate-release tablet (100 mg metoprolol tartrate)
Study: 26034150
Drug: Pregabalin (optimized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (optimized to 300 or 450 mg/day)
Study: 23824561
Drug: Early referral
Normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early referral for psychosocial treatment
Study: 21798429
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 5 mg/kg/day
Study: 21798429
Drug: Heparin/warfarin (started
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin/warfarin (started within 24 h of heparin lead-in; target INR: 2.0 to 3.0)
Study: 21798429
Drug: Both ASA
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both ASA and heparin/warfarin
Study: 19205162
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for tinnitus, 8 weeks duration
Study: 14616414
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg twice daily with voriconazole 200 mg twice daily
Study: 14616414
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily with voriconazole 200 mg twice daily
Study: 14616414
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with voriconazole 200 mg twice daily
Study: 10800240
Drug: Inhalation sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation sedation
Study: 8833544
Drug: Biperiden lactate
Normalized name: biperiden lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden lactate (4 mg)
Study: 3883170
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for six weeks
Study: 31305464
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor agonist (GLP-1RA) treatment for 6 months
Study: 29361042
Drug: Acetyl-L-Carnitine (ALC)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-Carnitine (ALC) 1000 mg three times a day for 24 weeks
Study: 17392729
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (200 ml t.i.d. for 10 days)
Study: 16334158
Drug: 111In-HMFG1-F(ab')2 with
Normalized name: Crotalidae immune F(ab')2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 111In-HMFG1-F(ab')2 with lysine co-infusion
Study: 16334158
Drug: 111In-HMFG1-F(ab')2 without
Normalized name: 111In-Pentetreotide
DrugBank: Indium In-111 pentetreotide (DB11835)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 111In-HMFG1-F(ab')2 without lysine co-infusion
Study: 12468959
Drug: Terlipressin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (1 mg/4 h intravenously for 7 days)
Study: 20337077
Drug: Two-visit endodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-visit endodontic treatment
Study: 22379833
Drug: Dahuangzhechong pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dahuangzhechong pills
Study: 19646862
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta without antithrombotic therapy
Study: 19646862
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta with antithrombotic therapy
Study: 16456674
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g EAA mixture
Study: 16456674
Drug: CHO +
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO + EAA supplement
Study: 14743972
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose theophylline (USRT)
Study: 14743972
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses theophylline (USRT)
Study: 11185672
Drug: Fixed-combination metformin/glyburide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-combination metformin/glyburide tablets (500 mg/2.5 mg and 500 mg/5 mg)
Study: 11185672
Drug: Metformin/glyburide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin/glyburide (500 mg/5 mg) tablet with food
Study: 11185672
Drug: Metformin/glyburide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin/glyburide (500 mg/5 mg) tablet in fasted condition
Study: 9382122
Drug: Ibandronate 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 0.5 mg
Study: 9382122
Drug: Ibandronate 1
Normalized name: ibandronate 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 1 mg
Study: 12006327
Drug: Ibandronate (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (all doses)
Study: 9382122
Drug: Ibandronate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (2 mg)
Study: 1550171
Drug: Transdermal continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal continuous 17 beta‐estradiol, 0.05 mg/day, with transdermal cyclic norethindrone acetate, 0.25 mg/day
Study: 1550171
Drug: Oral continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral continuous conjugated equine estrogens, 0.625 mg/day, with oral cyclic dl‐norgestrel, 0.15 mg/day
Study: 3560612
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nifedipine (corinfar)
Study: 3560612
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg propranolol (anaprilin)
Study: 3560612
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg propranolol and 20 mg nifedipine
Study: 3560612
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg propranolol (anaprilin) and 30 mg nifedipine (corinfar)
Study: 31056685
Drug: Probiotics (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium lactis, 109 colony‐forming units per capsule) for 8 weeks
Study: 24370154
Drug: 240‐mg/mL contrast
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240‐mg/mL contrast material at 80 kVp
Study: 24370154
Drug: 300‐mg/mL contrast
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300‐mg/mL contrast material at 80 kVp
Study: 24370154
Drug: 370‐mg/mL contrast
Approvals — FDA: no, EMA: no, PMDA: no
Description: 370‐mg/mL contrast material at 120 kVp
Study: 22943970
Drug: DA-1229 10
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-1229 10 mg after a high-fat meal
Study: 22943970
Drug: DA-1229 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-1229 (various doses: 1.25, 2.5, 5, 10, 20, 40, 60 mg)
Study: 22943970
Drug: DA-1229 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-1229 (various doses)
Study: 11605809
Drug: Ceftibuten 200
Normalized name: ceftibuten 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten 200 mg twice daily
Study: 2653175
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg naloxone hydrochloride
Study: 2653175
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg naloxone hydrochloride
Study: 2653175
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg naloxone hydrochloride (single blind)
Study: 794422
Drug: Inactivated Mycoplasma
Normalized name: Mycoplasma pneumoniae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated Mycoplasma pneumoniae vaccine, 1-ml dose administered by jet-injection device.
Study: 794422
Drug: Phosphate-buffered saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate-buffered saline (placebo) administered similarly to control subjects.
Study: 794422
Drug: Inactivated Mycoplasma
Normalized name: Mycoplasma pneumoniae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated Mycoplasma pneumoniae vaccine
Study: 26252534
Drug: ASM-024 50
Normalized name: Asm-024 cation
DrugBank: Asm-024 cation (DB19385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASM-024 50 mg
Study: 26252534
Drug: ASM-024 200
Normalized name: Asm-024 cation
DrugBank: Asm-024 cation (DB19385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASM-024 200 mg
Study: 21727232
Drug: Escitalopram (12-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (12-week treatment)
Study: 21727232
Drug: Placebo (12-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (12-week treatment)
Study: 16732081
Drug: Intravenous fructose
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous fructose infusion (0.5 g . kg(‐1) . h(‐1) for 4 h, starting 3 h before induction of anesthesia)
Study: 16732081
Drug: Intravenous fructose
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous fructose infusion
Study: 9228213
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg per day
Study: 22089105
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) monotherapy for 9 weeks
Study: 22089105
Drug: Atenolol monotherapy
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol monotherapy for 9 weeks
Study: 22089105
Drug: Add-on therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on therapy with HCTZ after atenolol
Study: 22089105
Drug: Add-on therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on therapy with atenolol after HCTZ
Study: 16199188
Drug: TKA731 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: TKA731 (150 mg daily)
Study: 15206646
Drug: Betaxolol 0.50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 0.50% twice daily
Study: 11775949
Drug: Mifepristone 300
Normalized name: mifepristone 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 300 mg plus misoprostol 1,200 micrograms over 6 days
Study: 11775949
Drug: Mifepristone 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 150 mg plus misoprostol 600 micrograms over 3 days
Study: 8721493
Drug: Histamine injections
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine injections (0.1 micrograms each)
Study: 1807007
Drug: Sulindac (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (100 mg x 3 per day)
Study: 1807007
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (25 mg x 3 per day)
Study: 1807007
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg x 2 per day in slow releasing form)
Study: 6338381
Drug: 10-drug regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-drug regimen (modified LSA2-L2)
Study: 6338381
Drug: 4-drug regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-drug regimen (COMP)
Study: 25795948
Drug: Cowpea protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cowpea protein isolate (25 g/day)
Study: 25795948
Drug: Casein (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein (25 g/day)
Study: 23348922
Drug: Novel anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel anticoagulants (specific types not mentioned) in PROBE trials
Study: 23348922
Drug: Novel anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel anticoagulants (specific types not mentioned) in double-blind trials
Study: 23348922
Drug: Warfarin (VKA)
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (VKA) control in PROBE trials
Study: 23348922
Drug: Warfarin (VKA)
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (VKA) control in double-blind trials
Study: 25473213
Drug: Polydeoxyribonucleotide (PDRN)
Normalized name: Adenine Deoxyribonucleoside
DrugBank: Adenosine (DB00640)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polydeoxyribonucleotide (PDRN) administered intramuscularly (1 ampule, 3 mL, 5.625 mg, for 5 days) for 2 weeks and perilesionally (1 ampule, 3 mL, 5.625 mg, twice a week) for 4 weeks
Study: 11379344
Drug: Bionormalizer (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bionormalizer (18 g/day for 2 weeks)
Study: 1091127
Drug: Clofibrate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibrate (2 gm. daily)
Study: 28600953
Drug: Manualized cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manualized cognitive therapy (mCT)
Study: 28600953
Drug: Cognitive-behavioral treatment-as-usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment-as-usual (CBTAU)
Study: 26082625
Drug: SFC 50/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC 50/500 μg twice daily
Study: 23365106
Drug: WL+FAEE (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: WL+FAEE (4 g/d Omacor)
Study: 21274983
Drug: Erythromycin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (1000 mg)
Study: 10947692
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 mg.kg‐1 and succinylcholine 1 mg.kg‐1 (n = 40)
Study: 10947692
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 mg.kg‐1 and alfentanil 10 microg.kg‐1 (n = 40)
Study: 10947692
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 mg.kg‐1 and succinylcholine 1 mg.kg‐1 or Sevoflurane 8%
Study: 8997677
Drug: CC +
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC + GTR
Study: 1635933
Drug: Divitabs (sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divitabs (sustained release preparation)
Study: 1635933
Drug: Normal carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal carbamazepine preparation
Study: 26879069
Drug: High-dose rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rosuvastatin (20 mg/day, n = 18)
Study: 26879069
Drug: Low-dose rosuvastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rosuvastatin (2.5 mg/day, n = 19)
Study: 26879069
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of high-dose vs low-dose rosuvastatin
Study: 23065047
Drug: Topical antiglaucoma
Normalized name: ANTIGLAUCOMA MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antiglaucoma medication
Study: 14636346
Drug: Antiepileptic monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic monotherapy with prednisolone (1 mg/kg/day for 10 days, tapering over 4 days)
Study: 14636346
Drug: Antiepileptic monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic monotherapy alone
Study: 14636346
Drug: Antiepileptic monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic monotherapy with prednisolone
Study: 10389804
Drug: IV droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV droperidol 1.25 mg
Study: 1676594
Drug: Vecuronium 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.08 mg kg‐1
Study: 6350090
Drug: Lorajmine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorajmine (600 mg/day)
Study: 6350090
Drug: After therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: After therapy interruption
Study: 2932514
Drug: Indomethacin (a
Normalized name: indomethacin (as indomethacin sodium trihydrate) 1 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (a cyclooxygenase inhibitor)
Study: 2932514
Drug: Dazoxiben hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Dazoxiben (DB03052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dazoxiben hydrochloride (a thromboxane synthase inhibitor)
Study: 2932514
Drug: BM13.177 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: BM13.177 (a thromboxane receptor antagonist)
Study: 27537992
Drug: CF101 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF101 2 mg
Study: 23918683
Drug: Hydrocortisone 30
Normalized name: hydrocortisone 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 30 mg divided in 2 doses
Study: 23918683
Drug: Hydrocortisone 30
Normalized name: hydrocortisone 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 30 mg divided in 4 doses
Study: 18726610
Drug: Vehicle eye
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle eye drop solution
Study: 16029343
Drug: Levamisole 150
Normalized name: levamisole 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole 150 mg (or 100 mg for children)
Study: 14500148
Drug: Spinal Anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal Anesthesia (6 mg bupivacaine and 15 micro g fentanyl)
Study: 14500148
Drug: Psoas Compartment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psoas Compartment Block (40 mL of 1.5% mepivacaine)
Study: 1677910
Drug: Ficoll fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ficoll fractionated and Mafosfamide purged cells (50 micrograms/ml/1 x 10e7 MN cells)
Study: 6406454
Drug: Bupropion (50-450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (50-450 mg/day to 300-750 mg/day)
Study: 6406454
Drug: Amitriptyline (75-225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75-225 mg/day)
Study: 20137432
Drug: Social skills
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social skills training program (1 hour weekly for 12 weeks)
Study: 14769727
Drug: Emergency department
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency department treatment of COPD exacerbation
Study: 11686543
Drug: Losartan (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (25 mg/day)